



03-13-01

GAU1615 \$

CASE 4-20921/A

Docket Number 4-20921/A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL138342775US  
Express Mail Label NumberMarch 12, 2001  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
WAGNER ET AL.

Art Unit: 1615

Examiner: Di Nola Baron,

APPLICATION NO: 09/202,805

FILED: MAY 7, 1999

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents  
Washington, D.C. 20231AMENDMENT

Sir:

In response to the outstanding Office Action, dated September 18, 2000, having a period of response set to expire December 18, 2000, Applicants request reconsideration of the application in view of the remarks below. Applicants also submit with this Response a Petition for a three (3) month extension of time.

REMARKS

Claims 1-25, 28-55 are pending in this case. All claims have been rejected under 35 U.S.C. 103(a) as allegedly unpatentable over Fujimura et al. (hereafter "Fujimura") and Ku et al. (hereafter "Ku").

Fujimura discloses the use of valsartan (3mg/kg) in combination with hydrochlorothiazide (HCTZ) (5 mg/kg) to treat male spontaneously hypertensive rats.

Ku discloses pharmaceutical compositions containing irbesartan (preferably 75-300 mg) with or without HCTZ (6.25 to about 25 mg) which are suitable for the creation of tablets to treat

RECEIVED  
MAR 16 2001  
TECH CENTER 1600/2900#13  
HAD  
3.22.01